The Department of Genetic Medicine at Weill Cornell leads a dynamic and innovative translational research program, advancing diverse fields such as Genetic Therapy and Personalized Medicine.
Our translational research program aims to leverage our expertise in genetic therapies and personalized medicine to develop clinical solutions that target the molecular causes of human diseases.
The Department of Genetic Medicine advances treatments and diagnostics through diverse clinical trials, including drug testing and research to better understand diseases.
The Department of Genetic Medicine at Weill Cornell leads a dynamic and innovative translational research program, advancing diverse fields such as Genetic Therapy and Personalized Medicine.
Our translational research program aims to leverage our expertise in genetic therapies and personalized medicine to develop clinical solutions that target the molecular causes of human diseases.
The Department of Genetic Medicine advances treatments and diagnostics through diverse clinical trials, including drug testing and research to better understand diseases.
Intracellular degradation of newly synthesized collagen.
Publication Type
Review
Authors
Rennard S, Stier L, Crystal R
Journal
J Invest Dermatol
Volume
79 Suppl 1
Pagination
77s-82s
Date Published
07/01/1982
ISSN
0022-202X
Keywords
Collagen
Abstract
The intracellular degradation of newly synthesized collagen is a cellular pathway that accounts for the destruction of 10-60% of collagen synthesized by a variety of cell types prior to secretion. This pathway can serve in a regulatory role to limit the secretion of defective molecules, and, in response to some extracellular mediators, regulates the amount and type of collagens secreted. In addition, this pathway may contribute to the pathogenesis of a variety of conditions affecting the extracellular matrix including fibrosis, diabetes mellitus, and scurvy.